Clinical trial
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA)
NCT06568237 is registered in ClinicalTrials.gov with Teva Branded Pharmaceutical Products R&D LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA)
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- October 2, 2024
- Completion date
- September 15, 2027
- Enrollment
- 349 (actual)
- Sites
- 61
Conditions
As the registry lists them; a condition with its own page is linked.